Abstract
2/2020
vol. 6
Rifaximin alfa – application in gastrointestinal diseases in the practice of a family doctor in light of new guidelines
- Oddział Chorób Zakaźnych i Przewodu Pokarmowego, Klinika Chorób Zakaźnych i Chorób Wątroby Uniwersytetu Medycznego w Łodzi, Wojewódzki Specjalistyczny Szpital im. dr. Wł. Biegańskiego w Łodzi
Online publish date: 2020/06/09
In 2016, the Rome IV diagnostic criteria were announced, being the latest update of the diagnostic criteria for functional gastrointestinal disorders (FGIDs), determined in accordance with the new definition of disorders of intestine-brain interaction. In connection with the growing role of intestinal microbiota in the pathogenesis of numerous gastrointestinal diseases, including irritable bowel syndrome, it has also become necessary to update the Polish recommendations prepared by the Polish Society of Gastroenterology. The article presents the latest guidelines for the treatment of selected gastrointestinal diseases with rifaximin alpha restoring intestinal eubiosis.
Keywords
eubiosis, rifaximin alpha, irritable bowel syndrome, microbiota, small intestinal bacterial overgrowth, guidelines
Indexed in
Integrated with
